Back to search
FDAFDA · Food and drugs·Recall number D-0871-2023

Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc. Berwyn, PA 19312, NDC 69918-301-30

Published June 21, 2023 · Recall initiated: June 12, 2023

Summary

FDA records drug Class III recall D-0871-2023, published June 21, 2023 and initiated June 12, 2023. Recalling firm: Amring Pharmaceuticals Inc; Status: Terminated; Reported quantity: 48,989 bottles; Lot: Lots: X220317A and X220318A, exp. date 09/25. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

What to do

Voluntary: Firm initiated · Letter

Get an email if TRANEXAMIC ACID has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TRANEXAMIC ACID
Manufacturer
Amring Pharmaceuticals Inc
Distributor
Nationwide in the USA.
Lot
Lots: X220317A and X220318A, exp. date 09/25
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc. Berwyn, PA 19312, NDC 69918-301-30 recalled?

Yes. FDA published recall D-0871-2023 on June 21, 2023. Reported hazard: Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TRANEXAMIC ACID.